| Literature DB >> 24310399 |
Agnieszka Bronisz1,2, Yan Wang3, Michal O Nowicki1,3, Pierpaolo Peruzzi3, Khairul Ansari1, Daisuke Ogawa1,3, Leonora Balaj4, Gianluca De Rienzo1, Marco Mineo1, Ichiro Nakano3, Michael C Ostrowski2, Fred Hochberg4, Ralph Weissleder4, Sean E Lawler1,3, E Antonio Chiocca1,3, Jakub Godlewski1,3.
Abstract
Extracellular vesicles have emerged as important mediators of intercellular communication in cancer, including by conveying tumor-promoting microRNAs between cells, but their regulation is poorly understood. In this study, we report the findings of a comparative microRNA profiling and functional analysis in human glioblastoma that identifies miR-1 as an orchestrator of extracellular vesicle function and glioblastoma growth and invasion. Ectopic expression of miR-1 in glioblastoma cells blocked in vivo growth, neovascularization, and invasiveness. These effects were associated with a role for miR-1 in intercellular communication in the microenvironment mediated by extracellular vesicles released by cancer stem-like glioblastoma cells. An extracellular vesicle-dependent phenotype defined by glioblastoma invasion, neurosphere growth, and endothelial tube formation was mitigated by loading miR-1 into glioblastoma-derived extracellular vesicles. Protein cargo in extracellular vesicles was characterized to learn how miR-1 directed extracellular vesicle function. The mRNA encoding Annexin A2 (ANXA2), one of the most abundant proteins in glioblastoma-derived extracellular vesicles, was found to be a direct target of miR-1 control. In addition, extracellular vesicle-derived miR-1 along with other ANXA2 extracellular vesicle networking partners targeted multiple pro-oncogenic signals in cells within the glioblastoma microenvironment. Together, our results showed how extracellular vesicle signaling promotes the malignant character of glioblastoma and how ectopic expression of miR-1 can mitigate this character, with possible implications for how to develop a unique miRNA-based therapy for glioblastoma management.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24310399 PMCID: PMC3928601 DOI: 10.1158/0008-5472.CAN-13-2650
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701